Race Oncology lists on the ASX (RAC) with the mission to rescue Bisantrene and return it to the clinic.
Bisantrene re-discovered, new patents filed and orphan drug designation obtained.
Bisantrene was approved for marketing in France for the treatment of AML. Lederle was acquired by Wyeth, which was then acquired by Pfizer. In the process, the French registration was withdrawn.
Tested in more than 40 published phase II clinical trials to assess its efficacy and safety in a wide range of cancers. The studies covered more than 2,000 treated patients and revealed that Bisantrene was shown to possess low cardiotoxicity potential and useful therapeutic efficacy in several cancers, notably AML.
Bisantrene discovered in the United States by US Pharmaceutical company Lederle (a division of American Cyanamid).